Hemodynamic effects of urapidil, dilevalol and acebutolol in essential hypertension.
スポンサーリンク
概要
- 論文の詳細を見る
Hemodynamic effects of short-term (6 weeks) oral urapidil 84.0±7.8mg/day, dilevalol 142±33 mg/day and acebutolol 444±26 mg/day were investigated in 48outpatients with essential hypertension (WHO stage I and II). Hemodynamic studieswere made in the supine position by radioisotope dilution technique using <SUP>131</SUP>I humanserum albumin to measure total circulating blood volume (TCBV) and <SUP>99m</SUP>Tc in vivolabelled red cells to measure cardiac output and left ventiicular ejection fraction (LVEF).<BR>These three drugs reduced blood pressure (P<0.005) with various changes in heartrate (urapidil, 73±3 to 71±2 bpm, ns; dilevalol, 63±2 to 59±1 bpm, P<0.025, acebutolol, 73±2 to 62±1 bpm, P<0.005). Cardiac index (CI) decreased slightly ithe acebutolol-and dilevalol-treated groups, though the change was not significant inthe latter. Urapidil did not induce a decrease in CI. LVEF tended to increase in thesethree groups, though the changes were not siginificant. Total peripheral resistanceindex (TPRI) tended to decrease in the dilevalol group (2, 885±118 to 2, 504±86dyne·sec·cm<SUP>-5</SUP>·m<SUP>2</SUP>, P<0.005) andand in the urapidil group (2, 749±193 to 2, 471±163dyne·sec·cm<SUP>-5</SUP>·m<SUP>2</SUP>, ns), but did not in the acebutolol.<BR>Urapidil, dilevalol, and acebutolol were reported to have beta-blocking activity andintrinsic sympathomimetic activity (ISA) as common pharmacological properties.However, urapidil and dilevalol have alpha-blocking activity, acebutolol did not. Theresults in this study suggest that the less beta-blocking activity the drug has, the lesscardiosuppressive effects it induces, and the effects of cardiac blockade may beantagonized by ISA and afterload reduction for the heart.<BR>Urapidil may induce a decrease in TPRI by vascular alpha-receptor blockingactivity, and its cardiac beta-blockade was not exhibited in this study, though thepossibility may exist that it supressed a reflex-induced tachycardia and increase incardiac pump function. ISA of dilevalol on the vasculature was reported to induceperipheral vasodilation in animal study, and this coincided with the results in this study, however, the decrease in TPRI may be partially influenced by vascular alpha-receptorblockade.
- 一般社団法人 日本臨床薬理学会の論文
著者
-
高崎 泉
神奈川県立がんセシター循環器科
-
堀井 昌子
神奈川県立がんセシター循環器科
-
羽鳥 裕
横浜市立大学医学部第二内科
-
大塚 啓子
神奈川県立がんセシター循環器科
-
築山久 一郎
神奈川県立がんセシター循環器科
関連論文
- 37) 冠状動脈低形成と大動脈低形成を合併した1症例 : 日本循環器学会第109回関東甲信越地方会
- 特発性肺動脈拡張症の1例 : 日本循環器学会第104回関東甲信越地方会
- 放射線照射17年後に発症した収縮性心膜炎の1例 : 日本循環器学会第125回関東甲信越地方会
- 1)縦隔腫瘍と思われた下大静脈欠損症の1例 : 第75回日本循環器学会関東甲信越地方会
- 本態性高血圧症患者における心血行動態と脳循環の検討 : 第66回日本循環器学会関東甲信越地方会
- 本態性高血圧症の臨床的研究 : 病期における脳・心血行動態と運動負荷時の体液性因子の変動について
- 当院における開胸術後の心房細動の発生状況について : 統計学的検討 : 日本循環器学会第145回関東甲信越地方会
- 降圧薬治療(ACE阻害薬を含む)と癌
- II.診断と治療の進め方 7.降圧薬の開始時期と降圧目標
- 新しいβ遮断薬TN-891とDihydropyridine系Ca拮抗薬GJ-0956の本態性高血圧例における循環動態上の効果
- 本態性高血圧例における新しいCa拮抗薬 Monatepil (AJ-2615) の循環動態上の効果
- 本態性高血圧・高脂血症合併例における高脂血症治療薬 Pravastatin と Bezafibrate の効果
- 本態性高血圧例におけるCa拮抗薬SD-3211(Semotiadil Fumarate)の循環動態上の効果
- 1238 本態性高血圧における血管拡張性降圧薬(AII受容体拮抗薬、K channel開口薬、Ca拮抗薬)の循環動態上の効果
- 本態性高血圧における循環動態の縦断的な検討 : 口述発表 : 第57回日本循環器学会学術集会
- 悪性腫瘍の心転移についての臨床病理学的検討(日本循環器学会 第138回関東甲信越地方会)
- 48) Osler-Rendu-Weber症候群の1例 : 日本循環器学会第122回関東甲信越地方会
- 本態性高血圧のcentral hemodynamicsとβ遮断薬metoprololの効果
- 22)Sjogren症候群に合併したrenal tubular acidosisの1例 : 日本循環器学会第107回関東甲信越地方会
- 11) Tachycardia-bradycardia syndromeおよび巨大P波を主徴としたウイルス性心筋炎の1例 : 日本循環器学会第93回関東甲信越地方会
- 本態性高血圧の一次予防(高血圧発症の予測因子と一次予防効果) : 欧米諸国の研究成績を中心とした検討
- 放射線照射17年後に発症した収縮性心膜炎の1例
- Choice of antihypertensive agents in hemodynamic aspects to match pathophysiology and pharmacology in essential hypertension.
- :Cardiac Output/Cardiopulmonary Blood Volume in Essential Hypertension
- Haemodynamic Effects of Once Daily Atenolol in Essential Hypertension
- Hemodynamic effects of tilisolol, a new .BETA.-adrenergic blocking agent with vasodilating property, and doxazosin, a new .ALPHA.-adrenergic blocking agent, in essential hypertension.
- Effect of a HMG-CoA reductase inhibitor, pravastatin on essential hypertension combining hyperlipidemia.
- タイトル無し
- タイトル無し
- タイトル無し
- Hemodynamic effects of urapidil, dilevalol and acebutolol in essential hypertension.
- Effects of an ACE inhibitor, Perindopril in essential hypertension on circulatory dynamics.
- Effects of .BETA.1-selective .BETA.-blockers on hemodynamics in hypertension of elderly persons.
- Effect of .BETA.-blocker N-696 and .ALPHA.-blocker doxazosin on hemodynamics in essential hypertension.
- Hemodynamic Effects of Prazosin or Ecarazine as Adjuncts to Betaadrenergic Blockade with Metoprolol or Pindolol in the Treatment of Essential Hypertension
- タイトル無し
- Effect of .ALPHA. blocker, naftopidil on circulatory dynamics in essential hypertension.
- Effect on hemodynamics of a Ca antagonist, amlodipine, and an ACE inhibitor, cilazapril, in essential hypertension.
- Effect on circulatory dynamics in essential hypertension of new diuretic Torasemide(GJ-1090).
- Effects of Ca antagonist Lacidipine on circulatory dynamics in essential hypertension.